SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus

Despite recent advances in the research on oncolytic viruses (OVs), a better understanding of how to enhance their replication is key to improving their therapeutic index. Understanding viral replication is important to improve treatment outcomes based on enhanced viral spreading within the tumor mi...

Descripción completa

Detalles Bibliográficos

Autores principales:	Alkayyal, Almohanad A., Ajina, Reham, Cacciabue, Marco Polo Domingo, Alkayyal, Aaesha A., Saeedi, Nizar H., Hussain Alshehry, Taofik, Kaboha, Feras, Alotaibi, Mohammed A., Zaidan, Nada, Shah, Khalid, Alroqi, Fayhan, Bakur Mahmoud, Ahmad
Formato:	info:ar-repo/semantics/artículo
Lenguaje:	Inglés
Publicado:	Frontiers Media 2023
Materias:	Severe Acute Respiratory Syndrome Coronavirus 2 Oncology Melanoma Vesicular Stomatitis Virus Coronavirus del Síndrome Respiratorio Agudo Arave 2 Oncología Virus de la Estomatitis Vesicular SARS-CoV-2 Viroterapia Agente Anticancerígeno Virotherapy Anticancer Agent
Acceso en línea:	http://hdl.handle.net/20.500.12123/15220 https://www.frontiersin.org/articles/10.3389/fimmu.2023.1082191/full https://doi.org/10.3389/fimmu.2023.1082191